Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 30 | 2026 | 389 | 5.090 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 12 | 2026 | 48 | 1.970 |
Why?
|
| Immunosuppressive Agents | 17 | 2025 | 658 | 1.050 |
Why?
|
| Meningoencephalitis | 1 | 2021 | 19 | 0.690 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2021 | 18 | 0.690 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2021 | 19 | 0.690 |
Why?
|
| JC Virus | 1 | 2021 | 26 | 0.680 |
Why?
|
| Cross Infection | 1 | 2024 | 331 | 0.670 |
Why?
|
| Fingolimod Hydrochloride | 5 | 2024 | 34 | 0.640 |
Why?
|
| Interferon-beta | 6 | 2011 | 56 | 0.620 |
Why?
|
| Recurrence | 7 | 2025 | 1477 | 0.600 |
Why?
|
| Glioblastoma | 1 | 2021 | 344 | 0.520 |
Why?
|
| Ganglioglioma | 1 | 2016 | 21 | 0.490 |
Why?
|
| Immunologic Factors | 6 | 2026 | 189 | 0.490 |
Why?
|
| Dimethyl Fumarate | 4 | 2024 | 10 | 0.480 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 2 | 2025 | 35 | 0.430 |
Why?
|
| Glatiramer Acetate | 5 | 2025 | 17 | 0.360 |
Why?
|
| Brain Diseases | 2 | 2019 | 302 | 0.360 |
Why?
|
| Osteopontin | 1 | 2010 | 52 | 0.320 |
Why?
|
| Adult | 29 | 2026 | 31230 | 0.320 |
Why?
|
| Young Adult | 11 | 2025 | 10011 | 0.310 |
Why?
|
| Interleukin-17 | 1 | 2010 | 129 | 0.310 |
Why?
|
| Injections, Epidural | 1 | 2008 | 3 | 0.290 |
Why?
|
| Pneumocephalus | 1 | 2008 | 3 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2021 | 1264 | 0.290 |
Why?
|
| Lateral Ventricles | 1 | 2008 | 15 | 0.290 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2021 | 3864 | 0.290 |
Why?
|
| Dura Mater | 1 | 2008 | 28 | 0.290 |
Why?
|
| Middle Aged | 22 | 2026 | 28459 | 0.280 |
Why?
|
| Sarcoidosis | 1 | 2008 | 53 | 0.280 |
Why?
|
| Headache | 1 | 2008 | 109 | 0.270 |
Why?
|
| Humans | 46 | 2026 | 130599 | 0.270 |
Why?
|
| Crotonates | 2 | 2024 | 6 | 0.260 |
Why?
|
| Toluidines | 2 | 2024 | 6 | 0.260 |
Why?
|
| Hydroxybutyrates | 2 | 2024 | 31 | 0.260 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 1303 | 0.250 |
Why?
|
| Nitriles | 2 | 2024 | 162 | 0.240 |
Why?
|
| Female | 29 | 2026 | 70540 | 0.220 |
Why?
|
| Male | 26 | 2026 | 64580 | 0.210 |
Why?
|
| Adolescent | 15 | 2025 | 20814 | 0.210 |
Why?
|
| Patient Preference | 1 | 2026 | 147 | 0.210 |
Why?
|
| Brain | 7 | 2026 | 3209 | 0.210 |
Why?
|
| Africa South of the Sahara | 1 | 2024 | 121 | 0.210 |
Why?
|
| Intracranial Hypertension | 1 | 2025 | 137 | 0.200 |
Why?
|
| Immunotherapy | 2 | 2024 | 752 | 0.190 |
Why?
|
| Cost of Illness | 2 | 2020 | 291 | 0.180 |
Why?
|
| Methotrexate | 3 | 2009 | 337 | 0.180 |
Why?
|
| Retrospective Studies | 13 | 2025 | 17654 | 0.180 |
Why?
|
| Urinary Retention | 1 | 2021 | 18 | 0.180 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2021 | 19 | 0.170 |
Why?
|
| Herpes Simplex | 1 | 2022 | 56 | 0.170 |
Why?
|
| Alemtuzumab | 2 | 2020 | 89 | 0.170 |
Why?
|
| Adjuvants, Immunologic | 3 | 2009 | 389 | 0.170 |
Why?
|
| Drug Monitoring | 1 | 2024 | 285 | 0.170 |
Why?
|
| Decision Making | 1 | 2026 | 688 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2024 | 401 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 6782 | 0.160 |
Why?
|
| Methylprednisolone | 3 | 2009 | 95 | 0.150 |
Why?
|
| Health Expenditures | 2 | 2020 | 134 | 0.150 |
Why?
|
| Prescription Drugs | 1 | 2020 | 52 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 124 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 542 | 0.130 |
Why?
|
| Autoantibodies | 3 | 2025 | 438 | 0.130 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 625 | 0.130 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 97 | 0.120 |
Why?
|
| Aged | 7 | 2025 | 20939 | 0.120 |
Why?
|
| Dendritic Cells | 2 | 2011 | 433 | 0.120 |
Why?
|
| Spinal Cord | 4 | 2021 | 264 | 0.120 |
Why?
|
| Treatment Outcome | 7 | 2021 | 12901 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 978 | 0.100 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1498 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2025 | 14994 | 0.090 |
Why?
|
| Quality of Life | 1 | 2022 | 2086 | 0.090 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2011 | 2 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2011 | 650 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2009 | 301 | 0.090 |
Why?
|
| Electroencephalography | 1 | 2016 | 861 | 0.090 |
Why?
|
| Lymphocyte Activation | 2 | 2011 | 627 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8554 | 0.080 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2011 | 60 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 1088 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2024 | 698 | 0.080 |
Why?
|
| Child | 4 | 2025 | 26182 | 0.080 |
Why?
|
| United States | 5 | 2025 | 11814 | 0.080 |
Why?
|
| Infant | 2 | 2024 | 13302 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 230 | 0.080 |
Why?
|
| Linear Models | 2 | 2022 | 692 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2011 | 824 | 0.070 |
Why?
|
| Atrophy | 3 | 2021 | 245 | 0.070 |
Why?
|
| Bupivacaine | 1 | 2008 | 26 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 5226 | 0.070 |
Why?
|
| Low Back Pain | 1 | 2008 | 41 | 0.070 |
Why?
|
| Transplantation, Autologous | 3 | 2017 | 263 | 0.070 |
Why?
|
| Neuromyelitis Optica | 1 | 2008 | 33 | 0.070 |
Why?
|
| Prednisone | 1 | 2008 | 240 | 0.070 |
Why?
|
| Biopsy | 2 | 2008 | 1241 | 0.070 |
Why?
|
| Steroids | 1 | 2008 | 170 | 0.070 |
Why?
|
| Antibodies, Neoplasm | 1 | 2007 | 54 | 0.060 |
Why?
|
| Encephalitis, Viral | 1 | 2007 | 19 | 0.060 |
Why?
|
| Roseolovirus Infections | 1 | 2007 | 30 | 0.060 |
Why?
|
| Interferon beta-1a | 4 | 2009 | 23 | 0.060 |
Why?
|
| Disability Evaluation | 3 | 2017 | 191 | 0.060 |
Why?
|
| Herpesvirus 6, Human | 1 | 2007 | 54 | 0.060 |
Why?
|
| Meningioma | 1 | 2008 | 139 | 0.060 |
Why?
|
| Logistic Models | 2 | 2022 | 1823 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2008 | 210 | 0.060 |
Why?
|
| Acute Disease | 1 | 2008 | 1151 | 0.060 |
Why?
|
| Drugs, Investigational | 1 | 2005 | 27 | 0.050 |
Why?
|
| Financing, Personal | 1 | 2004 | 14 | 0.050 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2004 | 20 | 0.050 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2024 | 8 | 0.050 |
Why?
|
| Optic Neuritis | 1 | 2025 | 35 | 0.050 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2004 | 15 | 0.050 |
Why?
|
| Myelin Basic Protein | 1 | 2004 | 67 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 904 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2005 | 171 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 99 | 0.050 |
Why?
|
| Epitopes | 1 | 2005 | 321 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 218 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 1894 | 0.050 |
Why?
|
| Peptides | 2 | 2004 | 709 | 0.050 |
Why?
|
| Monocytes | 1 | 2004 | 335 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2004 | 597 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2004 | 232 | 0.050 |
Why?
|
| Interferon Type I | 1 | 2002 | 114 | 0.050 |
Why?
|
| Paraparesis | 1 | 2021 | 8 | 0.050 |
Why?
|
| Medicare | 1 | 2025 | 439 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 5087 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3817 | 0.040 |
Why?
|
| Injections | 1 | 2021 | 111 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1338 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2103 | 0.040 |
Why?
|
| Constipation | 1 | 2021 | 130 | 0.040 |
Why?
|
| Models, Economic | 1 | 2020 | 58 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 380 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 1131 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2023 | 329 | 0.040 |
Why?
|
| Office Visits | 1 | 2020 | 78 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2019 | 95 | 0.040 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 82 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 283 | 0.040 |
Why?
|
| Lactation | 1 | 2020 | 197 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 2682 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 1230 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2004 | 1692 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 179 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2011 | 2902 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 2 | 2009 | 228 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 1841 | 0.030 |
Why?
|
| Cooperative Behavior | 2 | 2009 | 222 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1232 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3711 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 566 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 1164 | 0.030 |
Why?
|
| Patient Selection | 2 | 2009 | 721 | 0.030 |
Why?
|
| Disease Progression | 2 | 2015 | 2201 | 0.030 |
Why?
|
| Risk Factors | 2 | 2024 | 10991 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 770 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 811 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 1677 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 4022 | 0.020 |
Why?
|
| Clonal Anergy | 1 | 2011 | 2 | 0.020 |
Why?
|
| Natalizumab | 1 | 2011 | 5 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2004 | 641 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2011 | 63 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 1218 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1234 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1934 | 0.020 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2008 | 20 | 0.020 |
Why?
|
| Autopsy | 1 | 2007 | 119 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7495 | 0.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2007 | 24 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 350 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2008 | 341 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2007 | 451 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 790 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 2007 | 327 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 671 | 0.010 |
Why?
|
| Chad | 1 | 2004 | 1 | 0.010 |
Why?
|
| Axons | 1 | 2007 | 388 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 130 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 31 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 49 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 118 | 0.010 |
Why?
|
| Income | 1 | 2004 | 135 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2004 | 100 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2004 | 333 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 1457 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2011 | 3828 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 312 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2126 | 0.010 |
Why?
|
| Data Collection | 1 | 2004 | 366 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 357 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 185 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 713 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 4689 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2004 | 538 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 1007 | 0.010 |
Why?
|
| Poverty | 1 | 2004 | 453 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 342 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 1311 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2002 | 495 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1919 | 0.010 |
Why?
|
| Cytokines | 1 | 2002 | 1339 | 0.010 |
Why?
|
| Animals | 2 | 2011 | 33829 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 18174 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 6237 | 0.010 |
Why?
|